Podrobný průvodce již brzy
Pracujeme na komplexním vzdělávacím průvodci pro Twin Pregnancy Risk Assessment. Brzy se vraťte pro podrobné vysvětlení, vzorce, příklady z praxe a odborné tipy.
Twin-to-Twin Transfusion Syndrome (TTTS) is a serious complication occurring almost exclusively in monochorionic diamniotic (MCDA) twin pregnancies — twins who share a placenta. In MCDA twins, vascular connections (anastomoses) between the two twins' circulations on the shared placenta are nearly universal. When these anastomoses are unbalanced, one twin (the 'donor') pumps blood to the other twin (the 'recipient') through arteriovenous connections, creating a progressive haemodynamic imbalance. The donor becomes hypovolaemic, oliguric, and growth-restricted with severe oligohydramnios, while the recipient becomes hypervolaemic with polyhydramnios, cardiac strain, and risk of hydrops. TTTS complicates approximately 10–15% of MCDA pregnancies and is responsible for 17% of all perinatal mortality in twins. Without treatment, severe TTTS has a mortality rate approaching 90% for one or both twins. The Quintero staging system (I–V) classifies severity: Stage I (polyhydramnios/oligohydramnios without bladder visualisation problems), Stage II (absent bladder in donor), Stage III (abnormal Doppler studies), Stage IV (hydrops), Stage V (demise of one or both twins). MCDA twins require intensive surveillance with fortnightly ultrasound from 16 weeks gestation, measuring maximum vertical pocket (MVP) depth in each sac. A cervical length below 25 mm on transvaginal ultrasound before 24 weeks significantly increases the risk of TTTS-related preterm birth. Laser photocoagulation of placental anastomoses (fetoscopic laser surgery) is the definitive treatment for Quintero Stage II–IV TTTS and has transformed outcomes, achieving survival of at least one twin in approximately 85% of cases.
TTTS diagnosis: MVP donor sac <2 cm (oligohydramnios) AND MVP recipient sac >8 cm before 20wks or >10 cm after 20wks. Quintero Stage I-V classification based on bladder, Doppler, and hydrops findings.
- 1Confirm chorionicity at 11–14 weeks using the lambda (dichorionic) or T (monochorionic) sign at the inter-twin membrane insertion. MCDA twins need fortnightly surveillance from 16 weeks.
- 2At each surveillance ultrasound: measure the maximum vertical pocket (MVP) of amniotic fluid in each twin's sac.
- 3If MVP in donor sac is below 2 cm (oligohydramnios) AND MVP in recipient sac exceeds 8 cm before 20 weeks or 10 cm after 20 weeks, TTTS is diagnosed.
- 4Apply Quintero staging: Stage I — MVP criteria met; Stage II — donor bladder not visible after 1 hour of observation; Stage III — abnormal Doppler (AREDF in umbilical artery, reversed ductus venosus a-wave, or pulsatile UV flow); Stage IV — hydrops (ascites, pleural/pericardial effusion, skin oedema) in either twin; Stage V — demise of one or both twins.
- 5Assess cervical length by transvaginal ultrasound at the time of TTTS diagnosis — cervical length below 25 mm at or below 24 weeks identifies high risk of preterm birth.
- 6For Stage II–IV TTTS at 16–26 weeks: refer urgently to a fetal medicine unit with fetoscopic laser capability. Laser photocoagulation of all anastomoses on the placental surface (Solomon technique) is the recommended treatment.
- 7Post-laser: monitor weekly then fortnightly; assess for complications (twin anaemia-polycythaemia sequence TAPS, reverse TTTS, intrauterine death of one twin).
TTTS would require MVP <2 cm in one sac and >10 cm (at >20 weeks) in the other
Both MVP values are within the normal range (2–10 cm at this gestation). TTTS criteria not met. Continue routine MCDA surveillance.
Prognosis with laser: 85% survival of at least one twin; 65–70% both twins survive
MVP criteria (donor <2 cm, recipient >8 cm before 20 weeks) confirm TTTS. Absent bladder in donor upgrades to Stage II. Laser treatment is recommended and has been shown superior to amnioreduction in Stage II–IV TTTS.
Without treatment, Stage III/IV TTTS has >80% mortality for one or both twins
Stage III is reached when Doppler abnormalities appear: AREDF (absent or reversed end-diastolic flow) in the umbilical artery, reversed ductus venosus a-wave, or pulsatile umbilical vein flow. Immediate transfer to fetal medicine centre.
TAPS occurs in 2–13% of cases after laser treatment, caused by residual microscopic anastomoses
TAPS is characterised by anaemia in the donor (MCA-PSV >1.5 MoM) and polycythaemia in the recipient (MCA-PSV <1.0 MoM). Management depends on severity and gestational age.
Fortnightly ultrasound surveillance of all MCDA twin pregnancies to detect early TTTS., representing an important application area for the Twin To Twin Risk in professional and analytical contexts where accurate twin to twin risk calculations directly support informed decision-making, strategic planning, and performance optimization
Quintero staging to guide management decisions and timing of referral for laser surgery., representing an important application area for the Twin To Twin Risk in professional and analytical contexts where accurate twin to twin risk calculations directly support informed decision-making, strategic planning, and performance optimization
Post-laser surveillance using MCA Doppler to detect TAPS and monitor fetal wellbeing., representing an important application area for the Twin To Twin Risk in professional and analytical contexts where accurate twin to twin risk calculations directly support informed decision-making, strategic planning, and performance optimization
Parental counselling about prognosis, treatment options, and long-term neurodevelopmental outcomes., representing an important application area for the Twin To Twin Risk in professional and analytical contexts where accurate twin to twin risk calculations directly support informed decision-making, strategic planning, and performance optimization
Academic researchers and university faculty use the Twin To Twin Risk for empirical studies, thesis research, and peer-reviewed publications requiring rigorous quantitative twin to twin risk analysis across controlled experimental conditions and comparative studies
Stage I TTTS management
{'title': 'Stage I TTTS management', 'body': 'Stage I TTTS is controversial — some centres offer early laser for Stage I, while others observe closely with weekly ultrasound. Approximately 30–50% of Stage I cases progress to higher stages; spontaneous resolution also occurs. Decision should be made at a specialist fetal medicine unit with involvement of the parents.'}
Late-onset TTTS (after 26 weeks)
{'title': 'Late-onset TTTS (after 26 weeks)', 'body': 'When TTTS is first diagnosed after 26 weeks, laser surgery has a higher technical failure rate. Amnioreduction is commonly used as a temporising measure to reduce polyhydramnios and prevent preterm labour. Early delivery at 34–36 weeks may be recommended depending on fetal condition and amniotic fluid.'}
Twin reverse arterial perfusion (TRAP) sequence
{'title': 'Twin reverse arterial perfusion (TRAP) sequence', 'body': "TRAP (also called acardiac twin) is a separate but related MCDA complication where one twin has no functioning heart (acardiac twin) and is perfused in reverse by the pump twin's circulation. Treatment is radiofrequency ablation of the acardiac twin's cord to prevent pump twin cardiac failure."}
Dichorionic twins
In the Twin To Twin Risk, this scenario requires additional caution when interpreting twin to twin risk results. The standard formula may not fully account for all factors present in this edge case, and supplementary analysis or expert consultation may be warranted. Professional best practice involves documenting assumptions, running sensitivity analyses, and cross-referencing results with alternative methods when twin to twin risk calculations fall into non-standard territory.
| Stage | Criteria | Prognosis (untreated) |
|---|---|---|
| I | MVP criteria met; donor bladder visible | May self-resolve; close surveillance |
| II | Donor bladder not visible after 60 min observation | >60% perinatal loss without treatment |
| III | Abnormal Doppler: AREDF, reversed DV a-wave, pulsatile UV | >80% loss without treatment |
| IV | Hydrops in either twin | >90% perinatal loss without treatment |
| V | Intrauterine death of one or both twins | Co-twin injury risk 20–40% |
What is the difference between MCDA and MCMA twins?
MCDA (monochorionic diamniotic) twins share a placenta but have separate amniotic sacs. They account for approximately 70% of identical (monozygotic) twin pregnancies. MCMA (monochorionic monoamniotic) twins share both the placenta and a single amniotic sac and are much rarer — they carry additional risks of cord entanglement. TTTS occurs in MCDA twins; MCMA twins face different complications.
How is TTTS different from selective fetal growth restriction?
Both conditions occur in MCDA twins but have different mechanisms. TTTS is caused by unbalanced arteriovenous anastomoses producing amniotic fluid discordance. Selective fetal growth restriction (sFGR) occurs when one twin has a significantly smaller portion of the shared placenta, leading to growth restriction without the characteristic fluid discordance of TTTS. The two conditions can coexist.
What is the Solomon laser technique?
The Solomon technique for fetoscopic laser surgery involves coagulation of all visible anastomoses on the placental surface, followed by coagulation of the tissue between all the anastomoses to create a complete vascular equatorial demarcation. This 'dichorionisation' of the placenta has been shown to reduce the risk of post-laser TAPS compared to selective laser coagulation of individual anastomoses.
What is the cervical length threshold for concern in TTTS?
A cervical length below 25 mm on transvaginal ultrasound at or before 24 weeks is the standard threshold for concern in MCDA twins with TTTS. Short cervix predicts preterm birth and may lead to cervical cerclage or progesterone therapy in addition to TTTS treatment. It also influences timing and urgency of laser surgery.
What are the long-term outcomes for TTTS survivors?
Major studies including the Eurofetus trial and TAPS follow-up data show that approximately 85% of TTTS twins surviving after laser have no major neurodevelopmental impairment. The recipient twin has slightly higher risk of cardiac dysfunction and polycythaemia-related complications. The donor twin has higher risk of anaemia and growth restriction. Overall, long-term outcomes are significantly better with laser than with amnioreduction.
What if TTTS occurs before 16 weeks or after 26 weeks?
Laser surgery is most effective between 16 and 26 weeks gestation. Before 16 weeks, the fetoscope cannot safely enter the amniotic cavity. After 26 weeks, amnio-reduction may provide temporary relief, and early delivery is considered if the fetus is at risk. Some centres with experience may offer laser up to 28 weeks in selected cases.
Can TTTS recur after laser treatment?
True TTTS recurrence after technically successful laser is rare (<5%) but possible if residual anastomoses remain. However, new complications such as TAPS (from microanastomoses) or reverse TTTS (where previously donor becomes recipient) can occur in 10–15% of cases post-laser. Close post-laser surveillance with MCA Doppler studies is essential. This is particularly important in the context of twin to twin risk calculations, where accuracy directly impacts decision-making. Professionals across multiple industries rely on precise twin to twin risk computations to validate assumptions, optimize processes, and ensure compliance with applicable standards. Understanding the underlying methodology helps users interpret results correctly and identify when additional analysis may be warranted.
What happens if one twin dies in MCDA pregnancy?
In MCDA pregnancy, the death of one twin carries significant risk to the co-twin — approximately 20–40% risk of intrauterine death of the survivor and 25–35% risk of serious neurological injury due to acute haemodynamic shifts through shared placental anastomoses. Urgent delivery and/or cord occlusion of the deceased twin may be considered depending on gestation. Neurodevelopmental follow-up of the survivor is essential.
Pro Tip
All monochorionic twin pregnancies should have chorionicity confirmed and documented at the 11–14 week scan. The fortnightly surveillance schedule from 16 weeks must begin without exception — TTTS can develop and deteriorate rapidly within 2 weeks, making compliance with surveillance appointments life-saving.
Did you know?
The first successful fetoscopic laser photocoagulation for TTTS was performed in 1990 by Yves Ville in France. Before this, TTTS was managed with repeated amnioreduction — a temporising measure with 50–60% perinatal mortality. Laser surgery transformed survival from under 20% to over 85% in just three decades, representing one of fetal medicine's most dramatic successes.
References
- ›Senat MV et al — Endoscopic laser surgery vs serial amnioreduction for TTTS (Eurofetus Trial) — NEJM 2004
- ›RCOG Green-top Guideline No. 51 — Management of Monochorionic Twin Pregnancy
- ›Quintero RA et al — Staging of twin-twin transfusion syndrome — J Perinatol 1999
- ›NICE — Twin and Triplet Pregnancy (NG137)